Eugeroic

Marketed • Armodafinil (Nuvigil, CRL-40982, CEP-10952, (R)-modafinil) – the (R)-enantiomer of modafinil • Modafinil (Provigil, Alertec, Modavigil, CRL-40476) – a racemic mixture of armodafinil and esmodafinil • Solriamfetol (Sunosi). • Pitolisant (Wakix). Discontinued • Adrafinil (Olmifon, CRL-40028, N-hydroxymodafinil) – a hydroxy-substituted derivative and prodrug of modafinil Never marketed • Esmodafinil (CRL-40983, (S)-modafinil) – the (S)-enantiomer of modafinil • Fladrafinil (CRL-40941, fluorafinil, bisfluoroadrafinil) – a bisfluoro-substituted derivative of adrafinil • Flmodafinil (CRL-40940, NLS-4, JBG01-41, bisfluoromodafinil, lauflumide) – a bisfluoro-substituted derivative of modafinil • Fluorenol ("hydrafinil") – a novel eugeroic structurally unrelated to modafinil and its analogues • Modafiendz (methylbisfluoromodafinil) – a methyl and bisfluoro-substituted derivative of modafinil ==Novel eugeroics==

The pharmaceutical company Cephalon, the original United States market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic. Of the more than twenty compounds preclinically tested in Cephalon's three-part drug discovery series, the compound fluorenol was selected as a lead. Many other modafinil analogues have also subsequently been developed, not specifically as wakefulness-promoting agents but for treatment of conditions like psychostimulant use disorder and motivational disorders. ==References==